Alnylam Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Alnylam Pharmaceuticals Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Headquarters city: Cambridge
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: ALNY
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001178670
EIN: 77-0602661
Wikidata ID: Q16974682

Board of directors

Follow this board

Amy W. Schulman · Director
Since 2023
Benjamin Cravatt · Director
Since 2026
Carolyn R. Bertozzi · Director
Since 2023
Charles Elliott Sigal · Director
Since 2023
Colleen F. Reitan · Director
Since 2023
David E. I. Pyott · Director
Since 2023
Dennis A. Ausiello · Director
Since 2023
Margaret A. Hamburg · Director
Since 2023
Marsha Fanucci · Director
Since 2023
Michael W. Bonney · Director
Since 2023
Olivier Brandicourt · Director
Since 2023
Peter N. Kellogg · Director
Since 2023
Phillip A. Sharp · Director
Since 2023
Stuart A. Arbuckle · Director
Since 2026
Yvonne Greenstreet · Director · Chief Executive Officer
Since 2023

Chief executives

Yvonne Greenstreet · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of May 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Stuart A. Arbuckle

95.8%
Yvonne Greenstreet

99.6%

Board connections

12 of this board's directors also sit on 19 other boards. 18 are in the same sector.

Shared director Other board Same sector +3 more in the list below

Vir Biotechnology Inc. Same sector
via Charles Elliott Sigal and Phillip A. Sharp
Autolus Therapeutics plc American Depositary Share Same sector
via Michael W. Bonney
BeOne Medicines Ltd. Same sector
via Olivier Brandicourt
BioMarin Pharmaceutical Inc. Same sector
via David E. I. Pyott
Elevance Health Inc.
via Amy W. Schulman
Eli Lilly and Company Same sector
via Carolyn R. Bertozzi
Fractyl Health Inc. Same sector
via Amy W. Schulman
Generate Biomedicines Inc. Same sector
via Marsha Fanucci
Immunic Inc. Same sector
via Michael W. Bonney
Kyntra Bio Inc. Same sector
via Benjamin Cravatt
Myriad Genetics Inc. Same sector
via Colleen F. Reitan
OmniAb Inc. Same sector
via Carolyn R. Bertozzi
Pliant Therapeutics Inc. Same sector
via David E. I. Pyott
Praxis Precision Medicines Inc. Same sector
via Stuart A. Arbuckle
Rani Therapeutics Holdings Inc. Same sector
via Dennis A. Ausiello
Rhythm Pharmaceuticals Inc. Same sector
via Stuart A. Arbuckle
Seres Therapeutics Inc. Same sector
via Dennis A. Ausiello
Tarsus Pharmaceuticals Inc. Same sector
via David E. I. Pyott
Vaxcyte Inc. Same sector
via Olivier Brandicourt

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $543,126; 2 purchases by 2 insiders
Sold, last 12 months: $36,854,336; 268 sales by 8 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 10, 2026	Charles Elliott Sigal Director	Open-market purchase	+1,600	$152.25	$243,600
Nov 10, 2026	David E. I. Pyott Director	Option exercise	+3,780	$71.99	$272,122
Nov 9, 2026	Amy W. Schulman Director	Open-market purchase	+1,910	$156.82	$299,526
Oct 2, 2026	SUPRAN BRYAN Officer (EVP, CLO and Secretary)	Open-market sale	−1,758	$226.88	$398,855
Sep 19, 2026	Yvonne Greenstreet Director, Officer (Chief Executive Officer)	Grant or award	+107	—	—
Jun 1, 2026	David E. I. Pyott Director	Option exercise	+3,830	—	—
Jun 1, 2026	David E. I. Pyott Director	Open-market sale	−921	$297.71	$274,191
Jun 1, 2026	David E. I. Pyott Director	Open-market sale	−1,175	$298.91	$351,219
Jun 1, 2026	David E. I. Pyott Director	Open-market sale	−1,222	$299.87	$366,441
Jun 1, 2026	David E. I. Pyott Director	Open-market sale	−495	$300.72	$148,856
Jun 1, 2026	David E. I. Pyott Director	Open-market sale	−17	$302.65	$5,145
May 20, 2026	Charles Elliott Sigal Director	Grant or award	+671	—	—
May 20, 2026	Amy W. Schulman Director	Grant or award	+838	—	—
May 20, 2026	Colleen F. Reitan Director	Grant or award	+671	—	—
May 20, 2026	David E. I. Pyott Director	Grant or award	+671	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Alnylam Pharmaceuticals Inc.

Who is the CEO of Alnylam Pharmaceuticals Inc.?

Yvonne Greenstreet is Alnylam Pharmaceuticals Inc.'s Chief Executive Officer.

How many directors are on Alnylam Pharmaceuticals Inc.'s board?

Alnylam Pharmaceuticals Inc.'s board has 15 directors: Amy W. Schulman, Benjamin Cravatt, Carolyn R. Bertozzi, Charles Elliott Sigal, Colleen F. Reitan, David E. I. Pyott, Dennis A. Ausiello, Margaret A. Hamburg, Marsha Fanucci, Michael W. Bonney and 5 others.

Are Alnylam Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Alnylam Pharmaceuticals Inc. insiders bought $543,126 of shares in 2 purchases and sold $36.9 million of shares in 268 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Alnylam Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="alnylam-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.